177 related articles for article (PubMed ID: 36184895)
1. Projecting cardiovascular deaths averted due to trans fat policies in the Eurasian Economic Union.
Rieger M; Rippin HL; Pinedo A; Whiting S; Farrand C; Wickramasinghe K; Breda JJ
Public Health Nutr; 2023 Dec; 26(S1):s41-s50. PubMed ID: 36184895
[TBL] [Abstract][Full Text] [Related]
2. Trans fatty acid elimination policy in member states of the Eurasian Economic Union: Implementation challenges and capacity for enforcement.
Demin A; Løge B; Zhiteneva O; Nishida C; Whiting S; Rippin H; Delles C; Karymbaeva S; Wickramasinghe K; Breda J
J Clin Hypertens (Greenwich); 2020 Aug; 22(8):1328-1337. PubMed ID: 32677762
[TBL] [Abstract][Full Text] [Related]
3. Development and application of the TFA macrosimulation model: a case study of modelling the impact of trans fatty acid (TFA) elimination policies in Brazil.
Nilson EAF; Khandpur N; da Silva Gomes F
BMC Public Health; 2022 Nov; 22(1):2010. PubMed ID: 36324096
[TBL] [Abstract][Full Text] [Related]
4. Denmark's Policy on Artificial Trans Fat and Cardiovascular Disease.
Restrepo BJ; Rieger M
Am J Prev Med; 2016 Jan; 50(1):69-76. PubMed ID: 26319518
[TBL] [Abstract][Full Text] [Related]
5. Report on the Audit on Burden of Osteoporosis in Eight Countries of the Eurasian Region: Armenia, Belarus, Georgia, Moldova, Kazakhstan, the Kyrgyz Republic, the Russian Federation, and Uzbekistan.
Lesnyak O; Bilezikian JP; Zakroyeva A;
Arch Osteoporos; 2020 Nov; 15(1):175. PubMed ID: 33156448
[TBL] [Abstract][Full Text] [Related]
6. Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs.
Rubinstein A; Elorriaga N; Garay OU; Poggio R; Caporale J; Matta MG; Augustovski F; Pichon-Riviere A; Mozaffarian D
Bull World Health Organ; 2015 Sep; 93(9):614-22. PubMed ID: 26478625
[TBL] [Abstract][Full Text] [Related]
7. Contribution of Trans-Fatty Acid Intake to Coronary Heart Disease Burden in Australia: A Modelling Study.
Wu JH; Zheng M; Catterall E; Downs S; Thomas B; Veerman L; Barendregt JJ
Nutrients; 2017 Jan; 9(1):. PubMed ID: 28106762
[TBL] [Abstract][Full Text] [Related]
8. FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan.
Lesnyak O; Zakroyeva A; Babalyan V; Cazac V; Gabdulina G; Ismailov S; Lobanchenko O; Rudenka E; Tsagareli M; Johansson H; Harvey NC; McCloskey E; Kanis JA
Arch Osteoporos; 2021 Jun; 16(1):87. PubMed ID: 34089424
[TBL] [Abstract][Full Text] [Related]
9. Fatty acid composition including trans-fatty acids in edible oils and fats: probable intake in Indian population.
Dixit S; Das M
J Food Sci; 2012 Oct; 77(10):T188-99. PubMed ID: 22950538
[TBL] [Abstract][Full Text] [Related]
10. Impact of Austria's 2009 trans fatty acids regulation on all-cause, cardiovascular and coronary heart disease mortality.
Grabovac I; Hochfellner L; Rieger M; Jewell J; Snell A; Weber A; Stüger HP; Schindler KE; Mikkelsen B; Dorner TE
Eur J Public Health; 2018 Oct; 28(suppl_2):4-9. PubMed ID: 30371837
[TBL] [Abstract][Full Text] [Related]
11. Public health economic evaluation of different European Union-level policy options aimed at reducing population dietary trans fat intake.
Martin-Saborido C; Mouratidou T; Livaniou A; Caldeira S; Wollgast J
Am J Clin Nutr; 2016 Nov; 104(5):1218-1226. PubMed ID: 27680991
[TBL] [Abstract][Full Text] [Related]
12. Trans-Fatty Acids and Cardiovascular Disease: Urgent Need for Legislation.
Wilczek MM; Olszewski R; Krupienicz A
Cardiology; 2017; 138(4):254-258. PubMed ID: 28946140
[TBL] [Abstract][Full Text] [Related]
13. [Cardiovascular disease and trans fatty acids: legal act necessary].
Wilczek MM; Olszewski R; Krupienicz A
Pol Merkur Lekarski; 2018 Feb; 44(260):71-74. PubMed ID: 29498371
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the Socio-Economic Benefits of Reducing Industrial Dietary Trans Fats: Modelling Study.
Pearson-Stuttard J; Critchley J; Capewell S; O'Flaherty M
PLoS One; 2015; 10(8):e0132524. PubMed ID: 26247848
[TBL] [Abstract][Full Text] [Related]
15. Estimated health benefits, costs, and cost-effectiveness of eliminating industrial trans-fatty acids in Australia: A modelling study.
Marklund M; Zheng M; Veerman JL; Wu JHY
PLoS Med; 2020 Nov; 17(11):e1003407. PubMed ID: 33137090
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of eliminating industrial and all trans fats in England and Wales: modelling study.
Pearson-Stuttard J; Hooton W; Critchley J; Capewell S; Collins M; Mason H; Guzman-Castillo M; O'Flaherty M
J Public Health (Oxf); 2017 Sep; 39(3):574-582. PubMed ID: 27613767
[TBL] [Abstract][Full Text] [Related]
17. Trans fatty acids: are its cardiovascular risks fully appreciated?
Nestel P
Clin Ther; 2014 Mar; 36(3):315-21. PubMed ID: 24636816
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Impact of Ruminant Trans Fatty Acids on Human Health: Important Aspects to Consider.
Kuhnt K; Degen C; Jahreis G
Crit Rev Food Sci Nutr; 2016 Sep; 56(12):1964-80. PubMed ID: 25746671
[TBL] [Abstract][Full Text] [Related]
19. Impact of WHO recommendations to eliminate industrial trans-fatty acids from the food supply in Latin America and the Caribbean.
Colón-Ramos U; Monge-Rojas R; Campos H
Health Policy Plan; 2014 Aug; 29(5):529-41. PubMed ID: 24150503
[TBL] [Abstract][Full Text] [Related]
20. Learning from international policies on trans fatty acids to reduce cardiovascular disease in low- and middle-income countries, using Mexico as a case study.
Pérez-Ferrer C; Lock K; Rivera JA
Health Policy Plan; 2010 Jan; 25(1):39-49. PubMed ID: 19741052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
